A real-world claims analysis found that adults with tardive dyskinesia treated with INGREZZA (valbenazine) had higher rates of continuing treatment and lower rates of switching medications compared to those on AUSTEDO XR (deutetrabenazine). The study, covering a six-month follow-up, showed 55.6% persistence with INGREZZA versus 48.1% with AUSTEDO XR, and fewer patients switched therapies in the INGREZZA group. These results highlight INGREZZA's potential for more durable treatment adherence, which is crucial for managing symptoms and improving quality of life in this patient population. The findings were presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting and support INGREZZA as a preferred first-line therapy for tardive dyskinesia.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
